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Abstract
Rationale: The role of PI (protease inhibitor) type Z heterozygotes
and additional rare variant genotypes in the gene encoding alpha-1
antitrypsin, SERPINA1 (serpin peptidase inhibitor, clade A, member 1),
in determining chronic obstructive pulmonary disease risk and
severity is controversial.
Objectives: To comprehensively evaluate the effects of rare
SERPINA1 variants on lung function and emphysema phenotypes
in subjects with significant tobacco smoke exposure using
deep gene resequencing and alpha-1 antitrypsin concentrations.
Methods: DNA samples from 1,693 non-Hispanic white
individuals, 385 African Americans, and 90 Hispanics with>20
pack-years smoking were resequenced for the identification of rare
variants (allele frequency, 0.05) in 16.9 kB of SERPINA1.
Measurements and Main Results:White PI Z heterozygotes
confirmed by sequencing (MZ; n= 74) had lower post-
bronchodilator FEV1 (P= 0.007), FEV1/FVC (P= 0.003), and greater
computed tomography–based emphysema (P= 0.02) comparedwith
1,411 white individuals without PI Z, S, or additional rare variants
denoted as VR. PI Z–containing compound heterozygotes (ZS/ZVR;
n= 7) had lower FEV1/FVC (P= 0.02) and forced expiratory flow,
midexpiratory phase (P= 0.009). Nineteen white heterozygotes for
five non-S/Z coding variants associated with lower alpha-1
antitrypsin had greater computed tomography–based emphysema
compared with those without rare variants. In African Americans, a
59 untranslated region insertion (rs568223361) was associated with
lower alpha-1 antitrypsin and functional small airway disease
(P= 0.007).
Conclusions: In this integrative deep sequencing study of
SERPINA1 with alpha-1 antitrypsin concentrations in a heavy
smoker and chronic obstructive pulmonary disease cohort, we
confirmed the effects of PI Z heterozygote and compound
heterozygote genotypes. We demonstrate the cumulative effects of
multiple SERPINA1 variants on alpha-1 antitrypsin deficiency, lung
function, and emphysema, thus significantly increasing the frequency
of SERPINA1 variation associated with respiratory disease in at-risk
smokers.
Keywords: chronic obstructive pulmonary disease; alpha-1
antitrypsin; SERPINA1; rare variant; emphysema
(Received in original form April 9, 2019; accepted in final form October 24, 2019 )
*M.K.H. and P.G.W. are Associate Editors and F.J.M. is Deputy Editor of AJRCCM. Their participation complies with American Thoracic Society requirements
for recusal from review and decisions for authored works.
Correspondence and requests for reprints should be addressed to Victor E. Ortega, M.D., Ph.D., Center for PrecisionMedicine, Wake Forest School of Medicine,
Medical Center Boulevard, Winston-Salem, NC 27157. E-mail: vortega@wakehealth.edu.
This article has a related editorial.
This article has an online supplement, which is accessible from this issue’s table of contents at www.atsjournals.org.
More information about the study and how to access SPIROMICS data is at www.spiromics.org.
Am J Respir Crit Care Med Vol 201, Iss 5, pp 540–554, Mar 1, 2020
Copyright © 2020 by the American Thoracic Society
Originally Published in Press as DOI: 10.1164/rccm.201904-0769OC on October 29, 2019
Internet address: www.atsjournals.org
540 American Journal of Respiratory and Critical Care Medicine Volume 201 Number 5 | March 1 2020
 
The strongest genetic risk factor for chronic
obstructive pulmonary disease (COPD) and
emphysema susceptibility has been the locus
coding for SERPINA1 (alpha-1 antitrypsin,
serpin peptidase inhibitor, clade A, member 1)
on chromosome 14q32. Alpha-1 antitrypsin
deficiency is caused by genetic variants in
SERPINA1, resulting in increased risk for
early-onset obstructive lung disease and
emphysema, specifically in cigarette
smokers. SERPINA1 variation has been
estimated to account for ,1% of all cases
of COPD and emphysema (1–3).
Traditionally, alpha-1 antitrypsin deficiency
is diagnosed based on serum alpha-1
antitrypsin levels and classified with protein
phenotyping (PI [protease inhibitor] typing)
through protein isoelectric focusing (PIEF).
Based on PIEF, PI type M is the major wild-
type phenotype associated with normal
alpha-1 antitrypsin levels and homozygotes
for this phenotype (MM) have a similar
COPD risk as the general population.
In individuals of European white
descent, themost frequent PI types associated
with alpha-1 antitrypsin deficiency are PI
type S due to low-frequency coding variants
at amino acid position 288 (Glu288Val,
rs17580) and PI type Z at position 366
(Glu366Lys, rs28929474) (4–6). Homozygotes
for the Lys366 allele (ZZ), Val288 allele (SS),
and compound heterozygotes (ZS) have
been associated with lower serum alpha-1
antitrypsin levels and an increased risk for
COPD and emphysema (2, 7, 8). The
influence of the PI Z heterozygote genotype
on COPD and emphysema risk and severity
is still controversial with multiple studies
showing contradictory results (9, 10). Earlier
PIEF-based studies suggested that MZ
heterozygotes with a history of smoking
have an increased risk for COPD and lower
lung function but were based on cohorts
with a minimal smoking history (without
the necessary gene–environment
interaction) or not ascertained for COPD
(9, 11, 12). More recent studies with targeted
genotyping have shown that PI type Z
heterozygote genotype was associated with
lower lung function, COPD, and computed
tomography scan measures of emphysema;
however, these analyses did not account for
additional rare SERPINA1 variation or
alpha-1 antitrypsin concentrations (13–15).
A genome-wide association study for
emphysema and two for Global Initiative for
Chronic Obstructive Lung Disease (GOLD)
grade 2 to 4 COPD have also identified loci
adjacent to SERPINA1, suggesting the
importance of rare variation at this locus
(13, 16–18). None of these studies
performed DNA sequencing to exclude the
effects of background rare variation in MZ
heterozygotes or for the identification of
novel pathogenic rare genotypes.
Sequencing of SERPINA1 is necessary
to confirm whether one PI Z allele is
sufficient to affect disease risk and severity,
and is essential for identifying additional
rare variants that could influence
pathogenesis (19). Altogether, MZ
heterozygotes and novel pathogenic rare
genotypes could increase the influence of
SERPINA1 on COPD risk and severity in
ever-smokers. We hypothesize that PI type Z
and additional rare variants cumulatively
affect lung function and emphysema, and,
therefore, COPD risk and severity in
subjects with significant tobacco smoke
exposure (3). Thus, we performed a deep
resequencing study of SERPINA1 in a
comprehensively characterized (including
alpha-1 antitrypsin concentration
measurements in a large subset), multiethnic
cohort from the NHLBI SPIROMICS
(Subpopulations and Intermediate
Outcomes Measures in COPD Study). The
results of this study have been previously
reported in abstract form (20, 21).
Methods
Study Population
SPIROMICS participants were 40 to 80
years of age with a smoking history >20
pack-years with COPD (GOLD spirometric
grades 1–4) and without COPD (22, 23).
Participants were comprehensively
characterized with annual pre- and post-
bronchodilator lung function measures for
up to 3 years, computed tomography scans,
and standardized questionnaires (22).
Alpha-1 antitrypsin concentrations were
obtained in 1,391 subjects using Myriad
RBM’s CustomMAP using Luminex xMAP
technology at the initial baseline visit.
Resequencing of SERPINA1
DNA samples from 1,693 non-Hispanic
white individuals (1,097 with alpha-1
antitrypsin concentrations [see baseline
characteristics in Table E1 in the online
supplement]), 385 African Americans
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(231 with alpha-1 antitrypsin
concentrations), and 90 Hispanics (63 with
alpha-1 antitrypsin concentrations) were
sequenced with an average depth of 61.8
reads per target region (3; median = 60.53)
for the identification of less common and
rare variants with minor allele frequencies
less than or equal to 0.05 in a 16.9 kB region
(chromosome 14, nucleotide position
94841102–94857987 based on human
genome assembly GRCh37 [hg19]) of
SERPINA1 consisting of the five coding
exons, four introns, and the 59 and 39
untranslated regions (UTRs) (23).
Resequencing services were provided
through the NHLBI Resequencing and
Genotyping Service. Twelve variants with
minor allele frequency less than or equal to
0.05 identified with sequencing, including PI
Z, were also genotyped and confirmed with
the Illumina OmniExpress HumanExome
BeadChip (Illumina, Inc.) and PI S with the
MassARRAY system (Sequenom, Inc.). A
flow diagram of the analytical methods is
shown as Figure 1.
Statistical Methods
SERPINA1 polymorphisms that had a call
rate less than or equal to 0.98 and common
variants that did not meet Hardy–Weinberg
expectations (P, 0.05) or showed
nonrandom missingness were excluded
with the exception of PI type Z, which did
not meet Hardy–Weinberg expectations
(P= 6.293 1026) owing to a strong
influence on COPD risk in white
individuals (24). We annotated variants
identified with resequencing based on
GRCh37 using National Center for
Biotechnology Information ClinVar, the
NHLBI Grand Opportunity Exome
Sequencing Program, Exome Aggregation
Consortium, International Genome Sample
Resource based on the 1000 Genomes
Project, and Online Mendelian Inheritance
in Man databases to determine PI type and
novelty (25–29).
Regression-based burden tests of PI Z,
S, and other rare variants were stratified by
self-reported ethnic group to detect gene-
level effects on the strongly correlated
co–primary outcomes of baseline post-
bronchodilator FEV1% predicted,
FEV1/FVC ratio, and computed tomography
scan evidence of emphysema based on
percentage low attenuation area of bilateral
lungs <2950 Hounsfield units (HFU)
(%<2950 HFU) at TLC (see Table E2)
(30). We subsequently analyzed individual
variants with regression-based allelic
association analyses. Based on the significant
co–primary outcome associations found
with burden tests and for PI Z (C/T alleles)
(15), we evaluated six collapsed genotype
groups based on the presence or absence of
PI Z, PI S, or other rare variant minor alleles
for which little or no a priori knowledge of
pathogenicity was available (VR designates
all non-Z and non-S rare variants). Shown as
Figure 1:
1. Subjects with two SERPINA1 variants
were grouped as 1) PI Z homozygotes
(ZZ), 2) PI Z compound heterozygotes
(ZS/ZVR), and 3) compound heterozygotes
without PI Z (SS/VRVR/SVR).
2. Subjects with one SERPINA1 variant
were grouped as 1) MZ heterozygotes
and 2) MS/MVR.
3. Subjects with no identifiable rare
variant, PI S, or Z were a single group
(No Z/S/VR).
Secondary, related outcomes included
computed tomography scan evidence of air
trapping based on percentage of low
attenuation area of bilateral lungs less than
or equal to 2856 HFU (%<2856 HFU) at
residual volume, small airway disease as
measured by computed tomography
scan–based parametric response mapping
of functional small airway disease
(PRMfSAD), and clinical outcome measures
(see Figure 1) (31). Analyses were
performed using JMPGenomics 6.0 (SAS
Institute Inc.) and PLINK v1.07 adjusted
for age, sex, study site, body mass index,
pack-years cigarette smoking, FVC%
predicted for forced expiratory flow,
midexpiratory phase (FEF25-75), height for
computed tomography scan measures, and
C-reactive protein for alpha-1 antitrypsin
concentrations (24). To account for
ancestry in African Americans and
Hispanics, whole-genome European,
African, and Native American percentage
ancestry was estimated using ADMIXTURE
for regression-based models (24, 32).
Haplotype analyses and phasing of
compound heterozygotes was performed
with 16 common tagging single nucleotide
polymorphisms (SNPs; r2< 0.5), PI Z, and S.
Luciferase Reporter Assay
To evaluate a rare, 59 UTR G-insertion
associated with alpha-1 antitrypsin
concentrations and PRMfSAD in African
Americans, the 59 UTR of SERPINA1
NM_000295 was synthesized and
homology inserted into the pNL3.2 Nano
luciferase plasmid. All experiments were
performed in triplicate; experimental
details, including PCR primers and
genomic coordinates, are provided in Table
E3 and the online supplement methods.
Results
SERPINA1 Variants in the SPIROMICS
Multiethnic Study Cohort
The baseline characteristics are shown by
ethnic group in Table 1. Non-Hispanic
At a Glance Commentary
Scientific Knowledge on the
Subject: The influence of the MZ
heterozygote genotype on chronic
obstructive pulmonary disease
phenotypes is controversial, with
multiple studies showing contradictory
results. Over the past decade, protein
isoelectric focusing and genotyping-
based studies in European white
individuals, including one large
genotyping study of African Americans
and white individuals, have
demonstrated that protease inhibitor Z
heterozygotes have lower lung function
and more emphysema when
appropriately evaluating at-risk
individuals with sufficient pack-years
smoking history. These studies did not
evaluate for the effects of other rare
variants with deep sequencing, were not
complemented by alpha-1 antitrypsin
measurements, and most cohorts had
lower smoking histories (,20 pack-
years) (8, 11, 12, 14, 15, 17, 18).
What This Study Adds to the Field:
This study is the most comprehensive
analysis of rare SERPINA1 variants in a
multiethnic cohort with significant
cigarette-smoking exposure ascertained
for a broad range of chronic obstructive
pulmonary disease severity, not alpha-1
antitrypsin deficiency. This study is the
first to perform deep gene sequencing
in combination with alpha-1 antitrypsin
concentrations to detect the cumulative
effects of protease inhibitors Z, S, and
additional rare SERPINA1 variants,
combined and independently (34).
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white individuals had a higher smoking
history (51.8 pack-years) than African
Americans (41.0 pack-years) or Hispanics
(46.8 pack-years) (P= 5.603 1025).
Post-bronchodilator FEV1% and
FEV1/FVC ratio was lower in white
individuals (71.8% predicted and 0.59,
respectively) compared with African
Americans (76.6% and 0.64) and Hispanics
(80% and 0.64; P= 0.0004 and P= 0.0001).
Computed tomography scan–based
emphysema based on percentage
<2950 HFU and air trapping based on
percentage>2856 HFU was highest in white
individuals (8.19% and 25.9%, respectively)
compared with African Americans (7.70%
and 22.2%) and Hispanics (4.89% and 20.0%;
P=0.0006 and P=3.803 1025). White
individuals (n=1,097; 1.98 mg/ml), African
Americans (n=231; 1.95 mg/ml), and
Hispanics (n=63; 1.80 mg/ml) had similar
alpha-1 antitrypsin concentrations (P=0.18).
The allele frequencies for all missense
and frameshift exonic SERPINA1 variants
are shown by ethnic group in Table 2,
including 16 coding variants confirmed with
array genotyping. PI Z, S, 21 additional rare
coding variants, and one 59 UTR nucleotide
insertion variant are shown as Figure 2. One
variant in white individuals (Ile317Thr) had
not been previously reported. White
individuals had 17 coding variants with an
allele frequency less than 0.05 and one
frameshift insertion resulting in a null
variant (Tyr184Terfs, PI type Q0Granite Falls),
of which 15 were unique to white
individuals. African Americans had eight
variants with a frequency less than 0.05
(including the benign PI M1/M4), four
unique to African Americans; whereas, in
Hispanics, four, two unique, rare variants
were identified. We identified 18 of 23
exonic coding SNPs identified in the NHLBI
Exome Sequencing Project (see Table E4),
plus seven additional rare coding variants
and a frameshift insertion (28).
Seven PI Z–containing compound
heterozygotes were identified among white
individuals: three with PI type S (ZS
genotype), two Ala308Ser, one PI type
M6Passau, and one PI type I. Two PI SS
homozygotes and three compound
heterozygotes without PI Z were identified
in white individuals: one PI S/Ile317Thr, one
PI S/PI F, and one PI F/Ala308Ser. The
baseline characteristics of compound
heterozygotes and nine PI Z homozygotes
385 African Americans
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Gene-Level Burden Testing by Ethnic Group:
Related, Secondary
Outcomes:
•  Lung Function
      •  FEF-25–75%
      •  Annual Rate of
         Change
•  Computed Tomography
   Scan–based Air Trapping
•  Computed Tomography
   Scan–based Functional
   Small Airways Disease
•  Clinical Outcomes
      •  BODE Index
      •  SGRQ
      •  Exacerbations
ZERO vs. vs.ONE TWO SERPINA1 Rare Variants (RV)
PI Type Z Association Tests Conditional on Additional Rare SERPINA1
Variants (Pi S And VR) By Ethnic Group:
Co-Primary Outcomes:
•  Lung Function
      •  FEV1% Predicted
      •  FEV1/FVC
•  Computed Tomography
   Scan–based Emphysema
•  1-Antitrypsin
SERPINA1 16.9kB region resequencing to identify rare variants (RV, allele frequency<0.05)






Figure 1. SERPINA1 genetic study flow diagram summarizes the sequential analytical steps for characterizing rare SERPINA1 variants in SPIROMICS. First,
burden tests for PIs (protease inhibitors) Z, S, and 21 additional rare exonic coding variants and 1 frameshift insertion, all with a minor allele frequency of less than
0.05, were performed by self-reported ethnic group to evaluate for gene-level associations with the co–primary outcomes (30). Second, individual rare variants were
analyzed with regression-based allelic association tests to further evaluate significant associations. Based on the strong effect of PI type Z variant on the co–primary
outcomes in white individuals, we performed association testing of this variant conditional on additional less common (PI S) and rare SERPINA1 variants. We
compared white individuals without a PI Z, S, or additional rare variant allele (no Z/S/VR, where VR designates all non-Z and non-S rare variants), heterozygotes for
non–PI Z rare variation (MS/MVR), PI Z heterozygotes without another rare variant (MZ), compound heterozygotes with non–PI Z rare variation (SS/SVR/VRVR), PI
Z–containing compound heterozygotes with PI S or additional rare variants (ZS/ZVR), and PI Z homozygotes (ZZ) to evaluate the effects of PI Z heterozygotes with
the confirmed absence of other rare variants and PI Z in compound heterozygotes with another rare variant. We performed similar analyses for secondary related
outcomes. BODE=body mass index, airflow obstruction, dyspnea, and exercise; FEF25–75= forced expiratory flow, midexpiratory phase; SGRQ=St. George’s
Respiratory Questionnaire; SPIROMICS=Subpopulations and Intermediate Outcomes Measures in Chronic Obstructive Pulmonary Disease Study.
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are shown as Table E5 (haplotype phases are
shown as Table E6). We identified 14
synonymous SNPs, 268 59 UTR variants,
103 intronic variants, and 122 39 UTR
variants, including 25 insertion-deletions
(see Table E7).
Effects of PI Type Z, S, and Additional
Rare SERPINA1 Variants on Lung
Function and Emphysema
Phenotypes
Based on gene-level burden testing, white
individuals with any two rare exonic
SERPINA1 variants, including PI Z and S
(two rare variants [2RVs]; n=21), had lower
FEV1 (0RVs=72.6%; 2RVs=50.2% predicted;
P= 3.583 1025), FEV1/FVC (0RVs= 0.59;
2RVs= 0.44; P= 3.523 1026), and FEF25-75
(0RVs=55.7%; 2RVs=27.1% predicted;
P=1.693 1025), as well as greater computed
tomography scan–based emphysema
(0RVs= 7.83%; 2RVs= 17.2%<2950 HFU;
P=1.473 1025), air trapping (0RVs=25.4%;
2RVs=46.5%<2856 HFU; P=2.893 1026),
and functional small airway disease
(0RVs=21.6%; 2RVs=34.4% PRMfSAD;
P=2.343 1025; Table 3) compared with white
individuals with 0RVs (n=1,411). White
individuals with 1RV (n=259) had a lower
FEV1/FVC (1RV=0.57; P=0.005), FEF25-75
(1RV=50.4% predicted; P=0.004), and greater
emphysema (1RV=9.43%<2950 HFU;
P=0.049) compared with those with 0RVs
(see Table 3). Rare variant associations were not
found in African Americans or Hispanics
(see Table E8).
Allelic association testing by ethnic
group is shown as Tables E9 to E14. As
previously demonstrated in white individuals,
the PI Z SNP (C/T alleles; Table 4) was
associated with lower post-bronchodilator
lung function and GOLD grade 2 or higher
COPD when comparing major allele
homozygotes (CC; n= 1,601) and
heterozygotes (CT; n= 81) (15). Compared
with major allele homozygotes, PI Z SNP
heterozygotes also had lower FEF25-75
(CC=55.1%; CT= 47.3%; P=0.01), greater
computed tomography scan–based emphysema
(CC=7.89%; CT=12.3%; P=0.01), air
trapping (CC=25.4%; CT= 33.6%; P=0.01),
and functional small airway disease
(CC=21.6%; CT=26.1%; P=0.02; see
Table 4). Haplotype analyses excluded
background haplotype effects (see Table E15).
No significant lung function or computed
tomography scan measure associations were
found for any other exonic variant (see
Tables E9–E14) or PI Z in African
Americans or Hispanics (see Table E16).
Effects of PI Type Z, S, and Specific
Rare SERPINA1 Variant Genotypes on
Lung Function and Emphysema
Phenotypes
Owing to the significant co–primary outcome
associations between white individuals with
0RVs versus 1RV or two SERPINA1 variants
(see Table 3) and PI Z genotypes (see
Table 4) but not PI S or other rare variants
(VR; see Tables E9 and E12), we grouped
white individuals into six genotype groups by
Table 1. Baseline Characteristics of the SPIROMICS Cohort
SPIROMICS Cohort Baseline Characteristics
Ethnic Group
Non-Hispanic
White Individuals African Americans Hispanics
Demographics
Subjects, n 1,693 385 90
Age, yr, mean (SD)* 65.2 (8.30) 58.2 (8.96) 60.8 (10.0)
Sex, F, n (%)* 751 (44.4) 207 (53.8) 34 (37.8)
BMI, mean (SD) 27.8 (5.06) 28.0 (6.06) 28.6 (5.29)
Pack-years, mean (SD)* 51.8 (26.4) 41.0 (17.4) 46.8 (25.8)
COPD diagnosis, n (%)* 1,191 (70.3) 206 (53.5) 52 (57.8)
COPD grade 2–4 diagnosis, n (%)* 921 (54.4) 167 (43.5) 36 (40.0)
Post-bronchodilator pulmonary function
Baseline FEV1, % predicted, mean (SD)* 71.8 (25.8) 76.6 (27.1) 80.0 (28.0)
Baseline FVC, % predicted, mean (SD)* 90.3 (17.7) 92.5 (20.1) 94.8 (19.3)
FEV1/FVC ratio, %, mean (SD)* 0.59 (0.16) 0.64 (0.17) 0.64 (0.17)
Clinical outcome measures
Hospitalization or ED visit last 12 mo, n (%) 163 (9.75) 80 (21.2) 16 (18.0)
St. George’s Respiratory Questionnaire, mean (SD) 32.1 (20.1) 37.8 (20.9) 34.5 (21.9)
BODE, mean (SD) 1.51 (1.94) 1.57 (1.91) 1.08 (1.68)
6-minute-walk distance, m, mean (SD)* 408.5 (118.1) 410.6 (135.5) 408.9 (90.2)
COPD assessment test, mean (SD) 13.5 (8.10) 15.9 (8.88) 15.4 (8.82)
Additional measures
Computed tomography evidence of emphysema,
TLC % area,2950 HFU, mean (SD)*
8.19 (10.2) 7.70 (11.1) 4.89 (7.73)
Computed tomography evidence of air trapping,
residual volume% area,2856 HFU, mean (SD)*
25.9 (21.0) 22.2 (23.2) 20.0 (21.0)
Computed tomography–based functional small
airways disease, PRMfSAD, %, mean (SD)*
21.9 (15.0) 17.1 (15.7) 16.8 (16.3)
Alpha-1 antitrypsin concentration, mg/ml, mean
(SD)†
1.98 (0.48) 1.95 (0.48) 1.80 (0.35)
Definition of abbreviations: BMI = body mass index; BODE=body mass index, airflow obstruction, dyspnea, and exercise; COPD=chronic obstructive
pulmonary disease; ED=emergency department; HFU=Hounsfield units; PRMfSAD= parametric response mapping of functional small airway disease;
SPIROMICS=Subpopulations and Intermediate Outcomes Measures in COPD Study.
*P,0.05 for the trend between ethnic groups.
†Serum alpha-1 antitypsin levels were measured in a subgroup of 1,097 non-Hispanic white individuals, 231 African Americans, and 63 Hispanics.
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collapsing PI Z–containing and non-Z
variant (PI S or VR) genotypes (Table 5 and
see Figure 1). These six genotype groups
included 1) those without PI Z, S, or other,
rare variants (“no Z/S/VR” or “those without
rare variants”; n=1,411); 2) heterozygotes for
non–PI Z rare variants (“MS/MVR”; n=132
MS; n=53 MVR); 3) PI Z heterozygotes (CT
SNP genotype) without another rare variant
confirmed by sequencing (designated as
“MZ”; n=74); 4) PI S homozygotes, PI S and
VR (non–PI Z) compound heterozygotes
(“SS/SVR/VRVR”; n=5); 5) PI Z–containing
compound heterozygotes (“ZS/ZVR”; n=7);
and 6) PI Z homozygotes (TT SNP genotype
designated as “ZZ”; n=9) are shown as
Figure 1 and Table 5. Stratifying between
these genotype groups characterized the
associations between 0RVs and 1RV (see
Table 3) by distinguishing effects of true MZ
heterozygotes from Z-containing compound
heterozygotes (ZS/ZVR) and non-Z
heterozygotes (MS/MVR; see Figure 1). For
the associations between 0RVs and 2RVs (see
Table 3), this genotype stratification
distinguished the known effects of ZZ
homozygotes from the effects of additional
rare variants in compound heterozygotes
with (ZS/ZVR) and without PI Z
(SS/SVR/VRVR; see Figure 1).
White MZ heterozygotes had a lower
FEV1 (64.3%; P= 0.007; Figure 3A) and
FEV1/FVC (0.54; P= 0.003; see Figure 3B),
as well as increased computed tomography
scan–based emphysema (12.3%; P= 0.02;
see Figure 3C) and air trapping (32.1%;
P= 0.03), compared with those without rare
variants (FEV1 = 72.6%; FEV1/FVC= 0.60;
emphysema = 7.83%; air trapping = 25.4%;
see Table 5). Z-containing compound
heterozygotes also had a lower FEV1/FVC
(0.42; P= 0.02; see Figure 3B) and FEF25-75
(20.1%; P= 0.009) compared with subjects
without rare variants (see Table 5). Hence,
the association between PI Z SNP
heterozygote (CT) genotype and lung
function is due to both MZ and Z-containing
compound heterozygotes (15). Non–PI Z
rare variant heterozygotes (MS/MVR) also
had a lower FEF25-75 (50.6%) compared with
subjects without rare variants (55.7%;
P= 0.03; see Table 5). White ZZ
homozygotes had lower lung function




16.1% [P= 0.0002]; see Figures 3A and 3B
and Table 5) and greater computed
tomography scan measures of emphysema
(24.3%; P= 8.523 1028; see Figure 3C), air
trapping (54.2%; P= 1.153 1028), and
functional small airway disease (35.8%;
P=6.833 1027) compared with subjects
without rare variants (see Table 5). Genotype
effects on emphysema and air trapping
were determined by the lower lung zone
emphysema in ZZ and MZ; however, upper
Table 2. SERPINA1 Polymorphisms Identified in the Coding Exons in SPIROMICS by Ethnic Group
SERPINA1 Variants* Minor Allele Frequencies
rs Number†
cDNA Nucleotide







rs28931570‡ c.187C.T Arg63Cys I 0.003 0.001 0
rs199687431‡ c.206C.T Ser69Phe — 0.0003 0 0
rs111850950‡ c.250G.A Ala84Thr M6Passau 0.0003 0 0
rs376616935 c.286A.G Thr96Ala — 0 0.001 0
rs709932‡ c.374G.A Arg125His M2/M4 0.16 0.04 0.12
rs112030253‡ c.514G.T Gly172Trp M2Obernburg 0.002 0 0
rs267606950 c.552delC Tyr184Terfs Q0Granite Falls 0.0003 0 0
rs1206520317 c.632A.G Tyr211Cys — 0.0003 0 0
rs6647‡ c.710T.C Val237Ala M1Ala/M1Val 0.22 0.56 0.24
rs28929470‡ c.739C.T Arg247Cys F 0.004 0 0
rs121912714 c.839A.T Asp280Val PLowell, Q0Cardiff 0.0009 0 0
rs17580‡ c.863A.T Glu288Val S 0.04 0.008 0.05
rs141095970‡ c.879C.A His293Gln — 0 0.001 0
rs772436715 c.880C.T Asp294Asn — 0.0003 0 0
rs141620200‡ c.922G.T Ala308Ser — 0.004 0 0
rs773222881 c.926G.A Ser309Asn — 0 0 0.006
pos 94845916 c.950A.G Ile317Thr — 0.0003 0 0
rs139964603‡ c.976G.A Val326Ile — 0 0.003 0
rs377739083 c.1048C.T Pro350Ser — 0.0003 0 0
rs201788603‡ c.1061C.T Ser354Phe SMunich 0.0009 0 0
rs201318727 c.1090A.G Ile364Val — 0.0003 0 0
rs143370956‡ c.1093G.A Asp365Asn PSt. Albans 0 0.001 0
rs201774333 c.1095C.G Asp365Glu — 0 0 0.006
rs28929474‡ c.1096G.A Glu366Lys Z 0.03 0.005 0.03
rs61761869‡ c.1177C.T Pro393Ser MWurzburg 0.0009 0 0
rs1303‡ c.1200A.C Glu400Asp M3 0.25 0.09 0.22
rs754885222 c.1211A.G Lys404Arg — 0.0003 0 0
Definition of abbreviations: cDNA=complementary DNA; PI = protease inhibitor; pos=position; SPIROMICS=Subpopulations and Intermediate
Outcomes Measures in Chronic Obstructive Pulmonary Disease Study.
Minor allele frequencies of missense and frameshift polymorphisms identified through resequencing of a 16.9 kB region of SERPINA1 are shown by ethnic
group.
*Variants are described by rs number, PI type based on protein isoelectric focusing, and amino acid coding change when indicated.
†Novel variation or those without an rs number are shown by nucleotide pos on chromosome 14.
‡Twelve less common and rare coding variants (minor allele frequency,0.05) and 3 common variants were genotyped with the Illumina OmniExpress
HumanExome BeadChip (Illumina, Inc.) and PI S (not covered by the Chip) using a Sequenom Array.
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lung zone emphysema was also increased in
ZZ (see Table E17). White SS/SVR/VRVR
showed a spectrum of baseline disease risk
and severity (see Table 5); however, tobacco
smoke exposure varied across these five
individuals (21.5–42.8 pack-years for two SS
homozygotes, 63.0–80.0 pack-years for two
SVR/one VRVR; see Table E5).
Effects of PI Type Z, S, and Additional
Rare SERPINA1 Variants on
COPD Risk
All white PI Z–containing compound
heterozygotes (n= 7) and ZZ homozygotes
(n= 9) had GOLD grade 1 to 4 COPD.
Of these, six of seven Z-containing
compound heterozygotes and 100% of ZZ
homozygotes had grade 2 to 4 COPD.
Grade 2 to 4 COPD was more frequent in
MZ (n= 49 [66.2%]) compared with white
individuals without rare variants (n= 748
[53.0%]; P= 0.02; see Table 5). Rare
SERPINA1 genotypes were not significantly
associated with COPD in African
Americans or Hispanics (see Table E18).
Effects of PI Type Z, S, and Additional
Rare SERPINA1 Variants on
Longitudinal Lung Function
Although there was a significant difference
in longitudinal decline of FEV1 and FVC
over 3 years in those with 2RVs compared
with those without rare variants (see
Table 3), there were no strong genotype-
specific associations (additive P. 0.05; see
Tables 4 and 5). Based on burden testing,
white individuals with any two of the rare
variants, including PI Z and S (n= 16), had
a higher rate of decline (FEV1 =20.14 L/yr
[P= 0.001]; FVC=20.16 L/yr [P= 0.009];
FEV1/FVC=20.02/yr [P= 0.02]) compared
with white individuals without rare variants
(n= 1,214; FEV1=20.04 L/yr; FVC=20.04
L/yr; FEV1/FVC=20.006/yr; see Table 3).
Effects of PI Type Z, S, and Additional
Rare SERPINA1 Variants on
Exploratory Clinical Outcomes
Body mass index, airflow obstruction,
dyspnea, and exercise (BODE) index was
higher in MZ (2.07; P= 0.006) and ZZ
subjects (5.00; P= 6.673 1027) compared
with those without rare variants (1.46),
whereas St. George’s Respiratory
Questionnaire scores were only higher in
ZZ subjects (total score = 57.3) compared
with those without rare variants (31.6;
P= 0.002; see Table E19). COPD
Assessment Test scores were higher in ZZ
(22.1; P= 0.007) and Z-containing
compound heterozygotes (20.6; P= 0.04)
compared with those without rare variants
(13.4; see Table E19). In white individuals,
COPD exacerbations requiring emergency
department visits or hospitalization were
more frequent in ZZ (n= 4 [44.4%])
compared with those without rare variants
(n= 131 [9.38%]; P= 0.02; see Table E19).
Effects of Rare SERPINA1 Variants on
Alpha-1 Antitrypsin Concentrations
PI Z SNP genotypes (C/T) were associated
with alpha-1 antitrypsin concentrations
in white individuals (P= 5.843 10246;
see Table 4). Alpha-1 antitrypsin
concentrations were lower in MS/MVR
(n= 113; 1.79 mg/ml; P= 1.233 10211),
MZ (n= 49; 1.22 mg/ml; P= 2.923 10237),
compound heterozygotes without PI Z
(n= 2; 1.20 mg/ml; P= 0.005), PI Z–
containing compound heterozygotes (n= 5;
0.87 mg/ml; P= 2.733 10210), and ZZ
homozygotes (n= 6; 0.88 mg/ml;
P= 7.133 10210) compared with those
without PI Z/S/VR (n= 922; 2.05 mg/ml; see
Table 5). Detailed genotype analyses based
on PI types Z, S, and additional rare
variants demonstrate effects on alpha-1
antitrypsin concentrations, which mirror
effects on lung function and emphysema
(Figures 4A–4C). Rare variant burden
testing excluding white subjects with either
PI Z and S demonstrated lower alpha-1
antitrypsin concentrations in those with 1
of 14 different rare variants (n= 38;
1.76 mg/ml) compared with those without
variants (n=922; 2.05 mg/ml; P=8.093 1026;
see Figure E1). African American (n=4;
1.30 mg/ml) and Hispanic MZ heterozygotes
(n=5; 0.91 mg/ml) had lower alpha-1
antitrypsin concentrations compared with
African Americans (n=368; 1.96 mg/ml;
P=0.03) and Hispanics (n=74; 1.82 mg/ml;
P=0.02) without rare variants (see Table E18).
Alpha-1 Antitrypsin Quantitative Trait
Loci Analyses
Association testing, 16.9 kB region-wide, for
alpha-1 antitrypsin concentrations of
SERPINA1 conditional on PI Z did not
identify loci within the 59 or 39 UTR
reaching region-wide Bonferroni-adjusted
significance (P= 1.03 1024 based on 493
variants tested; see Figures E2 and E3). Five
rare non–Z coding variants were at least
nominally associated with alpha-1
antitrypsin concentrations in white
individuals (Ile317Thr [coinherited with PI
S in an individual compound heterozygote;
P= 0.05; see Figures 4A–4C], PI I
[P= 0.0002], PI Q0Granite Falls [P= 0.01], PI S
[P= 5.933 1029], PI MWurzburg [P= 0.046];
see Figure E2 and Table E20), whereas no
Ser69Phe















































Figure 2. SERPINA1 variants identified in the promoter and coding exons in the SPIROMICS
multiethnic cohort. Missense and frameshift polymorphisms identified through resequencing of a
16.9 kB region of SERPINA1 containing the untranslated promoter and five coding exons of SERPINA1
in the SPIROMICS multiethnic cohort are shown by amino acid position, coding change, and protease
inhibitor type where available. Of the 26 exonic coding variants identified with resequencing, three were
the common and benign protease inhibitor types M1Ala/Val (Val237Ala, rs6647), M2/M4 (Arg125His,
rs709932), and M3 (Glu400Asp, rs1303). A newly identified missense variant is underlined. Variants only
found in white individuals are in blue text, those only in African Americans in red text (including an ethnic-
specific G-nucleotide 59 untranslated region insertion [underlined] evaluated with functional studies), and
those only in Hispanics in green text. SPIROMICS=Subpopulations and Intermediate Outcomes
Measures in Chronic Obstructive Pulmonary Disease Study.
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exonic rare variants were associated in
African Americans (see Table E21) or
Hispanics (see Table E22). In the entire
white cohort with sequencing data, we
collapsed associated variants (PI I, Q0Granite Falls,
MWurzburg) with rare variants showing with
mean concentrations <1.5 mg/ml in carriers,
the lowest 10th percentile, (PI SMunich [n=3;
1.5 mg/ml], PI Q0Cardiff or PLowell [n=1; 1.3
mg/ml]; see Table E20) to test for associations
in the absence of PI S and PI Z genotypes.
White heterozygotes with any one of these
five rare variants had increased computed
tomography scan–based emphysema (n=19;
9.92%) compared with those without rare
variants (n=1,409; 7.83%; P=0.02; Figure 5
and see Table E23).
Alpha-1 antitrypsin quantitative trait
loci analysis in AfricanAmericans conditional
on PI Z identified a G-insertion in the 59UTR
(25,368 bps relative to start codon,
rs568223361; see Figure 2) associated with
lower alpha-1 antitrypsin concentrations
with similar significance as PI Z (P=0.02; see
Figure E3). Five African Americans with this
insertion had greater functional small airway
disease (PRMfSAD= 43%) compared with
those without (17%; P=0.007; see Figure E4
and Table E24). Luciferase reporter
experiments indicate that this insertion
lowers alpha-1 antitrypsin expression (see
Figures E5A and E5B) through either altered
transcriptional or translational regulation (33).
Discussion
This study is the largest, deep targeted
resequencing analysis of SERPINA1
variation integrated with alpha-1
antitrypsin measurements in a
comprehensively characterized multiethnic
cohort of subjects with COPD and
unaffected cigarette smokers not
ascertained for alpha-1 antitrypsin
deficiency. Targeted DNA sequencing
provides deeper coverage compared with
whole-genome or whole-exome sequencing
for the identification of rare variants. In
addition, the heavy minimal smoking
history of >20 pack-years in the
SPIROMICS cohort provides an
opportunity to detect pathogenic variation
not possible in cohorts without sufficient
exposure because gene–environment
interactions are a necessary component for
the penetrance of the emphysema and
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Figure 3. Effects of rare SERPINA1 variant–containing genotypes on lung function and computed
tomography scan–based emphysema. Regression-based association testing compared white
individuals without PIs (protease inhibitors) Z, S, or other rare variants (No Z/S/VR); heterozygotes for
non–PI Z rare variants (MS [n=132] and MVR [n=53] heterozygotes); PI Z heterozygotes without
another rare variant (MZ); PI S and VR compound heterozygotes (SS, SVR, and VRVR); PI Z–containing
compound heterozygotes with PI S or additional rare variants (ZS/ZVR); and PI Z homozygotes (ZZ).
Compound heterozygotes with PI type Z and S or additional rare variants include three PI type ZS,
one PI type Z/PI M6Passau, one PI type Z/PI I, and two PI type Z/Ala
308Ser. Compound heterozygotes
without PI type Z included two PI type S homozygotes (SS), one PI type S/Ile317Thr, one PI type S/PI
type F, and one PI type F/Ala308Ser. Bars represent the means. Regression-based analyses adjusted
by study site, age, sex, body mass index, and pack-years smoking history for lung function ([A]
FEV1% predicted and [B] FEV1/FVC ratio). Models also included height for log-transformed computed
tomography scan–based emphysema based on percentage of the area in bilateral lungs with density
of 2950 Hounsfield units (HFU) or less ([C] log % bilateral area<2950 HFU).
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Thus, this study addresses long-
standing questions regarding the role of PI Z
genotypes in the pathogenesis of COPD and
emphysema while providing insight into
novel rare SERPINA1 genotype associations
in ever-smokers. First, this study confirms
that PI Z heterozygotes with a significant
cigarette smoking history have lower lung
function, greater airflow obstruction, and
greater computed tomography scan–based
quantitative measures of emphysema, air
trapping, and functional small airway
disease. The question of the effects of MZ
heterozygosity on COPD risk and severity is
an important issue that has been evaluated
over the past 40 years in mostly general
populations primarily limited by small
sample sizes, physician-based diagnoses, and
a failure to establish sufficient exposure to
tobacco smoke resulting in variable results
(9, 10, 12, 35). Irish MZ heterozygotes based
on PIEF with >20 pack-years smoking
history had a lower lung function and an
increased COPD risk compared with MM
ever-smokers, whereas no differences were
observed between those with ,20 pack-
years (11). In contrast to our study, these
subjects were not ascertained for COPD and,
on average, had normal lung function.
Recent genotyping studies of COPD
and controls with >10 pack-years smoking
history also found lower lung function and
higher risk for COPD, computed
tomography scan–based emphysema, and
air trapping in PI Z heterozygotes
compared with those without PI S or Z,
including what we described in a genome-
wide association study of the same
population (13–15). In conjunction with
prior studies, we confirm the effects of the
MZ heterozygote genotype on COPD and
emphysema phenotypes in current and ex-
smokers. In contrast to prior studies, we
assessed background variation with deep
sequencing of SERPINA1 (10–15). Hence,
we were able to demonstrate that the effects
of PI Z heterozygote CT genotype (see
Table 4) are determined by the combined
effects of true MZ and PI Z–containing
compound heterozygotes on alpha-1
antitrypsin concentrations, lung function,
measures of small airway disease, and
emphysema (see Table 5) (13–15, 36).
Second, we demonstrated that non–PI
Z rare SERPINA1 variants and PI S are
significantly associated with COPD
phenotypes in Z-containing compound
heterozygotes. Prior studies have shown








































































































































































Figure 4. Rare SERPINA1 variant genotypes and alpha-1 antitrypsin levels in non-Hispanic white
individuals and effects on lung function and computed tomography scan–based emphysema.
Detailed genotypes in white individuals are shown as those without a rare SERPINA1 variant (MM),
those with one rare variant (VR) that is not PI (protease inhibitor) type S or Z (MVR), those with one PI
type S allele and no other variant (MS), PI type Z heterozygotes (MZ), PI type S homozygotes (SS),
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heterozygotes are at an increased risk for
airflow obstruction and emphysema;
however, few studies have evaluated
Z-containing compound heterozygotes with
additional variation (7, 8). In our study,
white Z-containing compound heterozygotes
with four different rare variants had
increased airflow obstruction, impaired
small airway function, and lower alpha-1
antitrypsin concentrations (see Table 5) (10,
37). Pathogenic Z-containing compound
heterozygotes with a diversity of rare
variants, including Q0Granite Falls, PI I, and
PLowell, have been associated with alpha-1
antitrypsin deficiency and early-onset
severe emphysema in case reports (38–41).
Third, our study is the first to show that
multiple rare SERPINA1 variant genotypes,
independent of PI Z, impact alpha-1
antitrypsin deficiency and could serve as a
predictor of emphysema even among heavy
smokers with a single variant. We found a
cumulative effect of rare variation on
alpha-1 antitrypsin deficiency, independent
of PI Z and S (see Figure E1), similar to that
described in a general population (42). Of
these, we identified five non-S/Z variants
associated with lower alpha-1 antitrypsin
concentrations and cumulatively associated
with computed tomography scan–based
emphysema in white heterozygotes (see
Figure 5) (10). White individuals with two
rare SERPINA1 variants, including PI S
homozygotes and compound heterozygotes
without PI Z, also had a higher rate of lung
function decline (see Tables 3 and 5),
demonstrating the diversity of genotypes
that influence disease progression beyond
PI Z genotypes (43, 44). The largest number
of rare SERPINA1 variants and phenotype
associations were found in white
individuals because of the smaller sample
size of African Americans and Hispanics,
which also resulted in a potential lack of
power to detect associations in these
minority racial groups. Despite this
limitation, this is the largest SERPINA1
sequencing study in a minority cohort of
ex-smokers and COPD with alpha-1
antitrypsin concentrations that identified a
rare 59 UTR variant unique to African
Americans associated with functional small
airway disease, a putative precursor to
emphysema, and alterations in alpha-1
antitrypsin expression (37). The clinical
impact of this G-insertion needs to be
confirmed in larger racially diverse cohorts.
We tested for associations between
SERPINA1 variation and multiple
phenotypes, resulting in multiple tests.
The strong effects of SERPINA1 variation
in rare compound heterozygotes
demonstrated gene-level variant
interactions that justified a tiered approach
starting with burden testing (see Figure 1)
to minimize multiple comparisons. In
addition, the three co–primary outcomes
are interrelated (see Table E2), resulting in
association tests that are not independent.
Another limitation is that sequencing does
not distinguish compound heterozygotes,
including singleton variants versus two
variants occurring on the same
chromosome. The low alpha-1 antitrypsin
concentrations in compound heterozygotes
provide supportive evidence that we
identified true compound heterozygotes
(see Tables 3 and 5, Table E5, and Figures
4A–4C). Finally, the analysis of small
samples sizes of rare genotype subgroups is
a major statistical challenge inherent to the
analysis of rare variants, which could have
weak effects, no effects, or opposing
beneficial effects not detected with
traditional association tests or collapsing
methods. For instance, whereas
Z-containing compound heterozygotes
showed statistical trends similar to ZZ
homozygotes, non-Z compound
heterozygotes and SS homozygotes showed
a spectrum of baseline disease risk and
severity (see Tables 5 and E5), which could
relate to differences in individual variant
effect sizes or tobacco smoke exposure, and




























Arg63Cys, PI I (N=9)
Pro393Ser, PI Mwurzburg (N=3)
Ser354Phe, PI SMunich (N=3)
Asp280Val, PI Q0Cardiff (N=3)







Figure 5. Effects on non-PI (protease inhibitor) type S or Z rare SERPINA1 variants associated with
alpha-1 antitrypsin concentrations on computed tomography scan–based emphysema in non-
Hispanic white individuals. Regression-based analyses were adjusted by study site, age, sex, pack-
years smoking history, body mass index, and height. Bars represent the means, red dots on the right
column represents subjects without rare SERPINA1 variants (common, major allele homozygotes),
and the dots of multiple colors on the right column represent different heterozygotes for one of five
different rare SERPINA1 variants associated with lower alpha-1 antitrypsin concentrations (P=0.05)
or with mean concentrations <1.5 mg/ml, excluding PI type S and Z. HFU=Hounsfield units.
Figure 4. (Continued). compound heterozygotes with PI type S except PI type Z (SVR), PI type S and Z-containing compound heterozygotes (SZ), Z-containing
compound heterozygotes with additional rare variants except PI type S (ZVR), and PI type Z homozygotes (ZZ), as shown. MVR heterozygotes included those with
Lys404Arg (n=1), Pro393Ser (PI Mwurzburg; n=3), Ile
364Val (n=1), Ser354Phe (PI SMunich; n=2), Pro
350Ser (n=1), Ala308Ser (n=7), Asp280Val (PI PLowell, Q0Cardiff;
n=1), Arg247Cys (PI F; n=8), Tyr211Cys (n=1), Tyr184Terfs (PI Q0Granite Falls; n=1), Gly
172Trp (PI M2Obernburg; n=5), Ser
69Phe (n=1), and Arg63Ser (PI I; n=6). ZVR
compound heterozygotes included one PI Z/PI M6Passau, one PI Z/PI I, and one PI Z/Ala
308Ser. SVR compound heterozygotes included one PI S/Ile
317Thr.
Regression-based analyses were adjusted by study site, age, sex, body mass index, and pack-years smoking history for lung function ([A] FEV1% and [B]
FEV1/FVC ratio). Models also included height for (C) log-transformed computed tomography scan–based emphysema based on percentage of the area in bilateral
lungs with density of 2950 Hounsfield units (HFU) or less (% area<2950 HFU). a1AT=alpha-1 antitrypsin.
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challenge of variable effects was also
important for non-Z/S rare variation for
which we leveraged alpha-1 antitrypsin
quantitative trait loci analyses to identify five
pathogenic variants cumulatively associated
with emphysema in white individuals and a
rare insertion associated with functional
small airway disease in African Americans.
Using targeted, deep DNA sequencing
and comprehensive phenotyping, we have
demonstrated the potential for sequencing
as a complementary test to the measurement
of alpha-1 antitrypsin concentrations for the
identification of novel variant determinants
for COPD and emphysema risk and
progression (19). We used next-generation
sequencing to detect novel and known rare
variation, including insertions or frameshift
variation, and ethnic-specific variants that
would not have been found in SNP-based
genotyping platforms primarily based on
European descent populations. Sequencing
distinguishes null variants (Q0Granite Falls,
Q0Cardiff) that falsely appear as homozygote
MM or ZZ genotypes on PIEF, as well
as similar PI types that have varying
pathogenic effects (normal M, MWurzburg,
M6Passau, PSt. Albans, PLowell, S, SMunich).
DNA sequencing definitively demonstrated
that MZ heterozygotes with the confirmed
absence of background rare variation and
Z-containing compound heterozygotes
associated with COPD and emphysema.
We also used alpha-1 antitrypsin
concentrations in conjunction with
computed tomography scan–based
measures and in vitro functional studies to
identify novel, at-risk non-Z heterozygote
subgroups. These findings need to be
evaluated in larger cohorts with sequencing
but justifies the sequencing of SERPINA1 in
a subgroup of at-risk smokers with COPD,
emphysema, and low alpha-1 antitrypsin
concentrations in the absence of two
pathogenic SNPs covered by chip
genotyping panels. Commercial testing kits
already perform resequencing in those with
alpha-1 antitrypsin deficiency if SERPINA1
panel genotyping is negative (45). A similar,
step-wise approach for CFTR resequencing
is standard for individuals with clinical
features of cystic fibrosis and elevated sweat
chloride concentrations despite negative
CFTR panel genotyping (46). CFTR
sequencing has identified over 2,000
variants of which 346 variants are known to
cause cystic fibrosis and are critical to the
selection of targeted modulator therapies
(47, 48).
Based on the frequency of Z-containing
compound heterozygotes, MZ heterozygotes,
and additional rare variant heterozygote
genotypes associated with emphysema
(see Table E23 and Figure 5) in white
individuals from SPIROMICS (6.4%), the
impact of SERPINA1 variation in the
smoking general population could be more
than ninefold greater when compared with
the prevailing hypothesis (ZZ/ZS combined
frequency = 0.7%). Based on the cumulative
deleterious effects of multiple rare
SERPINA1 genotypes, we should no longer
consider SERPINA1 variation a rare cause
of COPD and emphysema but as a
common and important pathogenic
determinant of disease risk and severity. As
the costs of next-generation sequencing and
high-throughput genotyping decline, the
identification and study of diverse
SERPINA1 variation could lead to the
development of comprehensive genotyping
panels for the identification of a larger
number of at-risk genotype subgroups. This
would allow early targeted smoking
cessation or other targeted, precision
approaches for the individualized prevention
and treatment of COPD and emphysema
related to alpha-1 antitrypsin deficiency. n
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